Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its second quarter 2022 financial results and corporate update on August 4, 2022. The company will release its Q2/2022 press release at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast through the Investors section of Arbutus' website. The company focuses on innovative therapeutics for viral diseases, including Hepatitis B and coronaviruses, and is advancing its lead compound, AB-729, in multiple phase 2 clinical trials.
- AB-729 is the only RNAi therapeutic with evidence of immune re-awakening.
- Ongoing phase 2 clinical trials for AB-729 show potential for a functional cure for chronic HBV.
- None.
WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022. The schedule for the press release and conference call/webcast are as follows:
| • | Q2/2022 Press Release: | Thursday, August 4, 2022 at 7:30 a.m. ET |
| • | Q2/2022 Conference Call/Webcast: | Thursday, August 4, 2022 at 8:45 a.m. ET |
| • | Domestic Dial-In Number: | (800) 715-9871 |
| • | International Dial-In Number: | (646) 307-1963 |
| • | Conference ID Number: | 5109143 |
A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (800) 770-2030 or (609) 800-9909, and reference conference ID: 5109143.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are developing a RNAi therapeutic, an oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When will Arbutus Biopharma announce its Q2 2022 financial results?
What time is the Arbutus Biopharma Q2 2022 conference call?
How can I access the Arbutus Biopharma conference call?
What is the focus of Arbutus Biopharma's research?
